Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.

European journal of haematology - 1 Mar 2011

Ali Dina, Jönsson-Videsäter Kerstin, Deneberg Stefan, Bengtzén Sofia, Nahi Hareth, Paul Christer, Lehmann Sören

Abstract excerpt

BACKGROUND: APR-246 belongs to a new generation of the compounds that restore normal p53 function in cells with mutated or wild type p53. The purpose of this study was to examine the effects of APR-246 alone and in combination with other drugs in acute myeloid leukemia (AML) cells. METHODS: Prima...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aza Compounds
Share to bcl-2-Associated X Protein
Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytarabine

Share to Daunorubicin

Share to Drug Synergism

Share to Tumor Suppressor Protein p14ARF

Share to Vidarabine

Source

Identifiers

PMID: 21114538
DOI: 10.1111/j.1600-0609.2010.01557.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21114538-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.PMID 21114538Read ↗

APR-246 induces early cell death by ferroptosis in acute myeloid leukemiaSemantic proximity Read ↗

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cellsSemantic proximity Read ↗

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemiaSemantic proximity Read ↗

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.Semantic proximity Read ↗

Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.Semantic proximity Read ↗

APR-246 Enhances Colorectal Cancer Sensitivity to RadiotherapySemantic proximity Read ↗

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cellsSemantic proximity Read ↗

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.Semantic proximity Read ↗

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.Semantic proximity Read ↗

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.